Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17‐1A
Open Access
- 1 April 2003
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 105 (5) , 717-723
Abstract
Tumor cells might be susceptible to different effector functions of the immune system. This cytotoxic capacity has been utilized to analyze the prognostic significance of peripheral blood mononuclear cells (PBMC) in patients with metastatic colorectal carcinoma (CRC) treated with the monoclonal antibody (MAb)17‐1A. Such analysis might form the basis for future patient selection and may lead to improvements in therapeutic strategies. Between 1986 and 1998, 73 patients were treated with regimens containing MAb17‐1A. Prior to therapy, the lytic capability of PBMC was assayed against: K562 (4 hr assay), the CRC cell line SW948 (4 hr and 18 hr assays) and antibody‐dependent cellular cytotoxicity (ADCC, 18 hr assay). Since the study was performed over 13 years, the assays were checked for time‐related bias. Reproducibility over time was satisfactory. Patients exhibited a significantly higher cytotoxic capability in all 4 assays compared to healthy control donors. No correlation to clinical outcome was noted for 18 hr ADCC and 18 hr spontaneous cytotoxicity. Pretreatment natural killer (NK) cell cytotoxicity (K562) was significantly related to overall survival (OS), progression‐free survival (PFS), and response rate. OS for patients with high and low NK cell cytotoxicity was 71 vs. 30 weeks, respectively (p = 0.007). NK cell cytotoxicity (K562) was an independent prognostic factor for OS (p = 0.016). Pretreatment NK cell activity is a strong prognostic factor for patients with metastatic CRC receiving MAb17‐1A therapy and is a predictor for OS, PFS and response. These results should be considered when designing antibody‐based therapeutic protocols.Keywords
Funding Information
- Swedish Cancer Society
- Cancer Society in Stockholm
- King Gustaf V Jubilee Fund
- Cancer and Allergy Foundation
- Torsten and Ragnar Söderberg's Foundation
- Karolinska Institute Foundation
This publication has 35 references indexed in Scilit:
- Ga733/EpCAM as a Target for Passive and Active Specific Immunotherapy in Patients with Colorectal CarcinomaAnnals of the New York Academy of Sciences, 2000
- Downregulation of Innate and Acquired Antitumor Immunity by Bystander gamma delta and alpha beta T Lymphocytes with Th2 or Tr1 Cytokine ProfilesJournal of Interferon & Cytokine Research, 1999
- Natural killer cell activity in patients with hepatocellular carcinomaCancer, 1998
- Escape from Host-Antitumor ImmunityCritical Reviews™ in Oncogenesis, 1997
- Natural killer cytotoxicity in the diagnosis of immune dysfunction: Criteria for a reproducible assayJournal of Clinical Laboratory Analysis, 1990
- Lymphokine Activated Killer (LAK) Cells in Antibody Dependent Cellular Cytotoxicity (ADCC) Using MAb 17-1A: A Combination of Potential Usefulness in Tumor TherapyHybridoma, 1989
- Effect of Human Blood Mononuclear Cell Populations in Antibody Dependent Cellular Cytotoxicity (ADCC) Using Two Murine (CO 17-1A and Br55-2) and One Chimeric (17-1A) Monoclonal Antibodies Against a Human Colorectal Carcinoma Cell Line (SW948)Hybridoma, 1988
- Monocyte- and natural killer cell-mediated spontaneous cytotoxicity against human noncultured solid tumor cellsCellular Immunology, 1987
- Age-dependent decline of natural killer and antibody-dependent cell mediated cytotoxicity activity of human lymphocytes is connected with decrease of their acid phosphatase activityMechanisms of Ageing and Development, 1985
- Human Macrophages Armed with Murine Immunoglobulin G2a Antibodies to Tumors Destroy Human Cancer CellsScience, 1983